bcl6 enables ph+ acute lymphoblastic leukaemia cells survive bcr-abl1 kinase inhibition 
tyrosine kinase inhibitors tkis widely used treat patients leukaemia driven bcr-abl1 ref oncogenic tyrosine kinases23 recent efforts focused developing potent tkis also inhibit mutant tyrosine kinases45 however even effective tkis typically fail eradicate leukaemia-initiating cells lics6- often cause recurrence leukaemia initially successful treatment report discovery novel mechanism drug resistance based protective feedback signalling leukaemia cells response treatment tki identify bcl6 central component drug-resistance pathway demonstrate targeted inhibition bcl6 leads eradication drug-resistant leukaemia-initiating subclones 
